“Triomune-40 Tablets Composition of Stavudine, Lamivudine and Nevirapine, HIV Medication by Cipla”

Press Release (ePRNews.com) - New Delhi, India - Aug 30, 2017 - Oddway International prides itself on being a supplier of premium quality wholesale speciality medicines. With a large number of medicines being delivered to customers worldwide, a new addition Triomune-40 manufactured by Cipla containing Stavudine, Lamivudine and Nevirapine in their extensive portfolio of products ensures their 100% reliability.

Triomune 40 tablet is used to prevent HIV infection. This medication works by increasing the number of infection fighting cells in the body; inhibiting multiplication of viruses; stopping the reverse transcriptase from working, thus helps to control HIV-1 infection.

Oddway International has announced product catalogs with more than 30 categories and offers hundreds of quality products at reasonable prices in each category. They are proud of the fact that the “quality control” and “quality assurance”, they provide to national and international customers to improve health and well-being with high quality pharmaceutical products.

About Oddway International

Oddway International is a global pharmaceutical service provider offering a wide range of services to the pharmaceutical industry and healthcare sector. For over 7 years, their commitment to excellence and high service levels has gained them their reputation as leading partner to the industry and healthcare sector. Oddway International is the largest independent pharmaceutical wholesaler in India with a fast growing international network supplying medicines. They specialise in global supply to wholesalers, pharmacy groups, hospitals, private hospitals, specialist clinics, clinical trial providers, charities, NGO’s and many other healthcare providers.


Source : http://www.oddwayinternational.com

You may also like this  

CATEGORIES : Healthcare Medical
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login